Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT (amivantamab-vmjw)

Source :: PR Newswire. September 10, 2024
Publication Year :: 2024
Abstract: Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, Sept. 10, 2024 [...]

Subjects :: Johnson & Johnson
Central nervous system depressants -- Complications and side effects -- Research
Dexamethasone -- Research -- Complications and side effects
Pemetrexed -- Complications and side effects -- Research
Medical colleges -- Research
Lung cancer, Non-small cell -- Development and progression -- Research -- Care and treatment -- Complications and side effects
Pharmaceutical industry -- Research
Business
News, opinion and commentary
Lazcluze (Medication) -- Complications and side effects -- Research
Rybrevant (Medication) -- Complications and side effects -- Research

Tools